Article Information
History
- January 14, 2022.
Article Versions
- You are currently viewing Version 1 of this article (January 14, 2022 - 22:06).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Yue-Miao Zhang1,†,
- Xing-Zi Liu1,†,
- Miao-Miao Lin1,†,
- Jin-Can Zan1,†,
- Yi-Tong Hu1,
- Xiang-Qiu Wang1,
- Wen-Qi Wu1,
- Tai-Cheng Zhou2,
- Hong Zhang1,
- Ji-Cheng Lv1,*,
- Li Yang1,* and
- Zi-Jie Zhang3,*
- 1Renal Division, Department of Medicine, Peking University First Hospital, Renal Pathology Center, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China; Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, 100034, China
- 2Center Lab and Liver Disease Research Center, the Affiliated Hospital of Yunnan University, Kunming, Yunnan 650091, China
- 3State Key Laboratory for Conservation and Utilization of Bio-resource and School of Life Sciences, Yunnan University, Kunming, Yunnan 650091, China
- ↵*Correspondence to: Zi-Jie Zhang, PhD, zijiezhang{at}ynu.edu.cn and Li Yang, MD & PhD. li.yang{at}bjmu.edu.cn and Ji-Cheng Lv, chenglv{at}263.net
↵† Equal contribution
Posted January 14, 2022.
Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients
